[Form 4] PROTO LABS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Proto Labs (PRLB) Form 4: President & CEO Suresh Krishna bought 1,725 common shares on 08/04/2025 in open-market transactions coded “P.” The weighted-average purchase price was $43.51 (range $43.47-$43.53), implying an aggregate outlay of roughly $75.5 thousand. Following the purchase, Krishna’s direct beneficial ownership rose to 18,021 shares, up about 11% from the prior holding. No sales, derivative transactions, or other insiders were reported in this filing.

The form contains no amendments, 10b5-1 notation, or additional footnotes beyond the pricing breakdown, and it does not reference any derivative securities. The filing therefore reflects a single, straightforward insider purchase that increases executive equity exposure.

Positive

• CEO insider purchase: 1,725 shares bought at $43.51, increasing direct ownership to 18,021 shares.
• No insider sales or derivative disposals were reported in the filing, avoiding mixed signals.

Negative

• Purchase size is modest (~$75k), limiting its material impact on ownership alignment.
• No operational or financial metrics accompany the filing, offering limited insight into company performance.

Insights

Securities Analyst

TL;DR: CEO’s $75k open-market buy modestly lifts insider ownership, a mildly positive governance signal.

An open-market purchase by the top executive typically aligns management with shareholders. Although the dollar value is small relative to Proto Labs’ market cap, the 1,725-share addition increases Krishna’s direct stake to 18,021 shares, suggesting incremental commitment. No offsetting sales or derivatives dilute the signal. Given the limited size, the event is unlikely to move valuation materially but supports sentiment that leadership sees value near the $43 range.

Corporate Governance Expert

TL;DR: Clean Form 4 with no derivative activity; governance risk unchanged.

The filing shows a routine insider purchase with full pricing disclosure and timely submission (two trading days post-trade). Absence of 10b5-1 notation suggests discretionary buying, yet the dollar amount is relatively minor. No red flags—such as late filing, complex instruments, or simultaneous sales—appear. Overall governance profile remains stable; impact for investors is informational rather than transformational.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krishna Suresh

(Last) (First) (Middle)

5540 PIONEER CREEK DRIVE

(Street)

MAPLE PLAIN MN 55359

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Proto Labs Inc [ PRLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2025		P		1,725	A	$43.51(1)	18,021	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the weighted average price of 1,725 shares of common stock of Proto Labs Inc. purchased by the reporting person in multiple transactions on August 4, 2025 with purchase prices ranging from $43.47 to $43.53 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ W. Morgan Burns, Attorney-in-Fact	08/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many PRLB shares did the CEO buy on 08/04/2025?

Suresh Krishna purchased 1,725 common shares.

What was the purchase price for Proto Labs stock?

The weighted-average price was $43.51, with individual trades between $43.47 and $43.53.

How many PRLB shares does the CEO now own?

Following the transaction, Krishna directly owns 18,021 shares.

Were any derivative securities involved in this Form 4?

No. Only common stock purchases were reported; Table II shows no activity.

Does the filing reference a Rule 10b5-1 trading plan?

The form does not indicate that the purchase was made under a 10b5-1 plan.